HDAC-IN-79
Product Specifications
UNSPSC Description
HDAC-IN-79 (compound 4) is an orally active dual xanthine oxidase-HDAC inhibitor (Xanthine oxidase: IC50=6.6 nM; HDAC1: IC50=134 nM; HDAC2: IC50=284 nM; HDAC3: IC50=173 nM; HDAC6: IC50=1.32 nM;), with significant in vivo anti-hyperuricemia and anti-tumor activities. HDAC-IN-79 is the most potent cell growth inhibitor (IC50=0.706 μM) of leukemia HL60 cells, induces apoptosis and autophagy, and can regulate the expression levels of signature biomarkers associated with intracellular HDAC inhibition[1].
Target Antigen
Apoptosis; Autophagy; HDAC; Xanthine Oxidase
Type
Reference compound
Related Pathways
Apoptosis;Autophagy;Cell Cycle/DNA Damage;Epigenetics;Metabolic Enzyme/Protease
Field of Research
Cancer; Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/hdac-in-79.html
Smiles
CC(C)COC1=CC=C(C2=NC(C)=C(C(NCCCCCCC(NO)=O)=O)S2)C=C1C#N
Molecular Weight
458.57
References & Citations
[1]Liao Z Y, et al. Rationally designed febuxostat-based hydroxamic acid and its pH-Responsive nanoformulation elicits anti-tumor activity[J]. European journal of medicinal chemistry, 279: 116866.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-162910/HDAC-IN-79-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-162910/
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
